KR102222864B1 - 면역 관용 유도 및 면역진단을 위한 ｆｖｉｉｉ 펩타이드 - Google Patents

면역 관용 유도 및 면역진단을 위한 ｆｖｉｉｉ 펩타이드 Download PDF

Info

Publication number
KR102222864B1
KR102222864B1 KR1020197032106A KR20197032106A KR102222864B1 KR 102222864 B1 KR102222864 B1 KR 102222864B1 KR 1020197032106 A KR1020197032106 A KR 1020197032106A KR 20197032106 A KR20197032106 A KR 20197032106A KR 102222864 B1 KR102222864 B1 KR 102222864B1
Authority
KR
South Korea
Prior art keywords
ser
prt
homo sapiens
fviii
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020197032106A
Other languages
English (en)
Korean (ko)
Other versions
KR20190126189A (ko
Inventor
카타리나 노라 스타이니츠
반 헬덴 파울라 마리아 빌헬미나
비르기트 마리아 라이페르트
한스-페터 슈바르츠
하르트무트 에를리히
Original Assignee
박스알타 인코퍼레이티드
박스앨타 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 박스알타 인코퍼레이티드, 박스앨타 게엠베하 filed Critical 박스알타 인코퍼레이티드
Publication of KR20190126189A publication Critical patent/KR20190126189A/ko
Application granted granted Critical
Publication of KR102222864B1 publication Critical patent/KR102222864B1/ko
Assigned to 다케다 야쿠힌 고교 가부시키가이샤 reassignment 다케다 야쿠힌 고교 가부시키가이샤 권리의 전부이전등록 Assignors: 박스알타 인코퍼레이티드, 박스앨타 게엠베하
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
KR1020197032106A 2010-10-27 2011-10-27 면역 관용 유도 및 면역진단을 위한 ｆｖｉｉｉ 펩타이드 Expired - Fee Related KR102222864B1 (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US40740210P 2010-10-27 2010-10-27
US61/407,402 2010-10-27
US201161467894P 2011-03-25 2011-03-25
US61/467,894 2011-03-25
US201161502476P 2011-06-29 2011-06-29
US61/502,476 2011-06-29
PCT/US2011/058165 WO2012058480A1 (en) 2010-10-27 2011-10-27 Fviii peptides for immune tolerance induction and immunodiagnostics

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020137013231A Division KR102040867B1 (ko) 2010-10-27 2011-10-27 면역 관용 유도 및 면역진단을 위한 ｆｖｉｉｉ 펩타이드

Publications (2)

Publication Number Publication Date
KR20190126189A KR20190126189A (ko) 2019-11-08
KR102222864B1 true KR102222864B1 (ko) 2021-03-04

Family

ID=45349271

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020197032106A Expired - Fee Related KR102222864B1 (ko) 2010-10-27 2011-10-27 면역 관용 유도 및 면역진단을 위한 ｆｖｉｉｉ 펩타이드
KR1020137013231A Active KR102040867B1 (ko) 2010-10-27 2011-10-27 면역 관용 유도 및 면역진단을 위한 ｆｖｉｉｉ 펩타이드

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020137013231A Active KR102040867B1 (ko) 2010-10-27 2011-10-27 면역 관용 유도 및 면역진단을 위한 ｆｖｉｉｉ 펩타이드

Country Status (20)

Country Link
US (3) US8969524B2 (enExample)
EP (2) EP3260132B1 (enExample)
JP (2) JP6122780B2 (enExample)
KR (2) KR102222864B1 (enExample)
CN (2) CN103298482B (enExample)
AR (1) AR083586A1 (enExample)
AU (2) AU2011319747C1 (enExample)
BR (1) BR112013010362A2 (enExample)
CA (1) CA2815239C (enExample)
DK (1) DK2632479T3 (enExample)
EA (1) EA034494B1 (enExample)
ES (2) ES2639039T3 (enExample)
HK (1) HK1215442A1 (enExample)
MX (1) MX347805B (enExample)
NZ (2) NZ703514A (enExample)
PL (2) PL2632479T3 (enExample)
PT (1) PT2632479T (enExample)
SG (2) SG189914A1 (enExample)
TW (3) TWI580430B (enExample)
WO (1) WO2012058480A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006063031A2 (en) 2004-12-06 2006-06-15 Haplomics Allelic variants of human factor viii
PL2917232T3 (pl) * 2012-11-12 2017-09-29 Apitope International Nv Pochodzące od czynnika VIII peptydy do zastosowania w leczeniu hemofilii A
US10272163B2 (en) 2012-12-07 2019-04-30 The Regents Of The University Of California Factor VIII mutation repair and tolerance induction
US20160038575A1 (en) * 2013-03-15 2016-02-11 Haplomics, Inc. Compositions and methods for immune tolerance induction to factor viii replacement therapies in subjects with hemophilia a
WO2017180807A1 (en) 2016-04-15 2017-10-19 Baxalta Incorporated Method and apparatus for providing a pharmacokinetic drug dosing regiment
US20170128544A1 (en) * 2014-06-12 2017-05-11 University Of Hawaii Uses of Humanized Cobra Venom Factor for Reducing or Preventing Immunogenicity
WO2016120218A1 (en) * 2015-01-26 2016-08-04 Cellectis ANTI-CLL1 SPECIFIC SINGLE-CHAIN CHIMERIC ANTIGEN RECEPTORS (scCARS) FOR CANCER IMMUNOTHERAPY
US10896749B2 (en) 2017-01-27 2021-01-19 Shire Human Genetic Therapies, Inc. Drug monitoring tool

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003087161A1 (en) 2002-04-18 2003-10-23 Merck Patent Gmbh Modified factor viii
WO2009071886A1 (en) * 2007-12-04 2009-06-11 Apitope Technology (Bristol) Limited Fviii peptides and their use in tolerising haemophiliacs
WO2009095646A2 (en) 2008-01-28 2009-08-06 Circassia Limited Peptides from factor viii

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7485314B2 (en) * 2002-05-06 2009-02-03 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Induction of antigen specific immunologic tolerance
ATE427499T1 (de) * 2004-05-21 2009-04-15 Inst Systems Biology Zusammensetzungen und verfahren zur quantifizierung von serumglykoproteinen
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
SI2522717T1 (sl) 2006-01-04 2014-05-30 Baxter International Inc. Mediji celične kulture brez oligopeptidov
US7673687B2 (en) 2007-12-05 2010-03-09 Halliburton Energy Services, Inc. Cement compositions comprising crystalline organic materials and methods of using same
DE202007017320U1 (de) 2007-12-07 2008-02-28 Dittmann, Ludwig Vorrichtung zur Raumbeduftung
WO2009099991A2 (en) 2008-01-31 2009-08-13 The Brigham And Women's Hospital, Inc. Treatment of cancer
EP2385825B1 (en) 2008-11-07 2018-10-10 University of Connecticut Factor viii formulations

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003087161A1 (en) 2002-04-18 2003-10-23 Merck Patent Gmbh Modified factor viii
US20050256304A1 (en) * 2002-04-18 2005-11-17 Tim Jones Modified factor VIII
WO2009071886A1 (en) * 2007-12-04 2009-06-11 Apitope Technology (Bristol) Limited Fviii peptides and their use in tolerising haemophiliacs
WO2009095646A2 (en) 2008-01-28 2009-08-06 Circassia Limited Peptides from factor viii

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NCBI, GenBank accession number: AAD 16965.1 (2002.06.21.)*

Also Published As

Publication number Publication date
ES2912455T3 (es) 2022-05-26
JP6122780B2 (ja) 2017-04-26
AU2011319747C1 (en) 2016-07-14
TW201708251A (zh) 2017-03-01
EP3260132B1 (en) 2022-02-09
PL2632479T3 (pl) 2017-09-29
US20120135019A1 (en) 2012-05-31
MX2013004753A (es) 2013-09-13
SG189914A1 (en) 2013-06-28
NZ703514A (en) 2017-02-24
JP2014505014A (ja) 2014-02-27
EA201390617A1 (ru) 2013-10-30
CA2815239A1 (en) 2012-05-03
US9512198B2 (en) 2016-12-06
HK1215442A1 (zh) 2016-08-26
SG10201600656WA (en) 2016-02-26
MX347805B (es) 2017-05-15
AU2011319747B2 (en) 2016-01-07
AU2011319747A1 (en) 2013-05-02
CA2815239C (en) 2019-02-26
AR083586A1 (es) 2013-03-06
CN103298482A (zh) 2013-09-11
CN104926947A (zh) 2015-09-23
TW201231065A (en) 2012-08-01
US20150203567A1 (en) 2015-07-23
TWI580430B (zh) 2017-05-01
AU2016202155B2 (en) 2018-02-01
PL3260132T3 (pl) 2022-08-08
AU2016202155A1 (en) 2016-04-28
EA034494B1 (ru) 2020-02-13
CN103298482B (zh) 2015-08-19
KR20190126189A (ko) 2019-11-08
WO2012058480A1 (en) 2012-05-03
US8969524B2 (en) 2015-03-03
TW201730205A (zh) 2017-09-01
EP2632479B1 (en) 2017-06-14
US20170267743A1 (en) 2017-09-21
BR112013010362A2 (pt) 2016-08-02
DK2632479T3 (en) 2017-08-07
PT2632479T (pt) 2017-07-24
KR20130128404A (ko) 2013-11-26
EP3260132A1 (en) 2017-12-27
JP2017095463A (ja) 2017-06-01
KR102040867B1 (ko) 2019-11-07
NZ609474A (en) 2015-06-26
ES2639039T3 (es) 2017-10-25
EP2632479A1 (en) 2013-09-04

Similar Documents

Publication Publication Date Title
US9512198B2 (en) FVIII peptides for immune tolerance induction and immunodiagnostics
KR101592855B1 (ko) 암 백신 조성물
KR20240111754A (ko) 키메라 어댑터 폴리펩티드
CN111944021A (zh) Cd47亲和肽及其应用
JP6363996B2 (ja) 免疫原性が低下した凝固因子ｖｉｉｉ
HK1246211A1 (en) Fviii peptides for immune tolerance induction and immunodiagnostics
HK1246211B (en) Fviii peptides for immune tolerance induction and immunodiagnostics
HK1188954A (en) Fviii peptides for immune tolerance induction and immunodiagnostics
HK1188954B (en) Fviii peptides for immune tolerance induction and immunodiagnostics
EA043749B1 (ru) Пептиды фактора viii для индукции иммунной толерантности и иммунодиагностики

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20250226

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-OTH-PC1903 (AS PROVIDED BY THE NATIONAL OFFICE); TERMINATION CATEGORY : DEFAULT_OF_REGISTRATION_FEE

Effective date: 20250226

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20250226